Marksans Pharma Ltd

Marksans Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Marksans Pharma Ltd

₹ 185 0.68%
30 Oct 12:51 p.m.
marksanspharma.com BSE: 524404 NSE: MARKSANS
About

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products [1]

Key Points

Product Portfolio
OTC Products: (74% of FY24 revenue)
Include Pain Management, Cough and Cold, Digestive Remedies, Vitamins and Tonics, Skin Treatments, and Allergies.[1]
Prescription (Rx) Products: (26%)[2]
Includes cardiovascular, central nervous system (CNS), anti-allergic, anticancer, and anti-diabetic drugs.

Website BSE NSE
  • Market Cap ₹ 8,384 Cr.
  • Current Price ₹ 185
  • High / Low ₹ 359 / 162
  • Stock P/E 41.1
  • Book Value ₹ 30.5
  • Dividend Yield 0.44 %
  • ROCE 18.6 %
  • ROE 14.4 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 37.7% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 20.5%

Cons

  • Company has a low return on equity of 12.4% over last 3 years.
  • Company has high debtors of 171 days.
  • Promoter holding has decreased over last 3 years: -4.73%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap Nifty Microcap 250 Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
159 170 173 153 182 205 241 225 255 309 312 299 320
148 136 149 130 155 167 199 191 213 256 252 248 250
Operating Profit 12 34 24 23 27 37 42 34 41 52 60 52 70
OPM % 7% 20% 14% 15% 15% 18% 17% 15% 16% 17% 19% 17% 22%
19 21 16 4 33 16 1 12 8 31 23 7 2
Interest 1 1 1 1 0 0 0 0 0 0 0 0 0
Depreciation 5 5 4 4 5 8 8 7 7 7 7 8 8
Profit before tax 26 49 34 23 54 44 35 38 42 76 75 50 64
Tax % 25% 18% 26% 22% 19% 30% 27% 14% 24% 17% 26% 25% 24%
19 40 26 18 44 31 25 33 32 63 55 38 48
EPS in Rs 0.47 0.99 0.64 0.39 0.98 0.69 0.56 0.73 0.71 1.39 1.22 0.83 1.06
Raw PDF
Upcoming result date: 13 November 2025

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
315 406 358 216 295 424 433 600 658 655 853 1,174 1,240
231 290 254 191 266 361 362 486 545 563 713 970 1,006
Operating Profit 84 116 104 24 29 63 71 114 114 92 140 204 234
OPM % 27% 29% 29% 11% 10% 15% 16% 19% 17% 14% 16% 17% 19%
3 3 9 7 7 8 0 31 42 60 62 70 63
Interest 15 13 6 4 8 7 7 5 4 4 1 1 1
Depreciation 9 9 15 15 12 9 12 15 18 17 29 29 31
Profit before tax 63 97 92 12 17 56 53 124 135 132 172 243 265
Tax % 12% 31% 22% 3% 25% 22% 28% 21% 23% 22% 22% 23%
56 67 71 12 12 44 38 98 104 103 134 188 204
EPS in Rs 1.44 1.64 1.75 0.28 0.30 1.07 0.93 2.40 2.54 2.27 2.95 4.15 4.50
Dividend Payout % 7% 7% 7% 18% 16% 5% 11% 10% 10% 22% 20% 19%
Compounded Sales Growth
10 Years: 11%
5 Years: 22%
3 Years: 21%
TTM: 34%
Compounded Profit Growth
10 Years: 11%
5 Years: 38%
3 Years: 22%
TTM: 68%
Stock Price CAGR
10 Years: 7%
5 Years: 29%
3 Years: 55%
1 Year: -34%
Return on Equity
10 Years: 12%
5 Years: 13%
3 Years: 12%
Last Year: 14%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 39 41 41 41 41 41 41 41 41 45 45 45
Reserves 108 305 369 378 388 430 465 559 744 1,066 1,177 1,338
103 62 53 73 67 78 11 14 14 8 8 11
127 119 71 54 61 64 83 127 167 226 285 361
Total Liabilities 376 527 534 546 557 612 600 741 966 1,345 1,516 1,755
67 90 97 94 88 103 115 129 136 144 272 383
CWIP 0 0 0 0 0 0 0 0 0 4 0 0
Investments 68 68 231 234 236 236 236 236 237 266 293 266
242 369 205 217 233 273 249 375 594 931 952 1,105
Total Assets 376 527 534 546 557 612 600 741 966 1,345 1,516 1,755

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
54 112 65 -14 16 20 108 107 56 52 34 31
-2 -29 -177 -8 -8 -20 -24 9 -128 -195 -114 17
-19 51 -52 21 -10 1 -82 -14 71 210 -26 -30
Net Cash Flow 33 134 -164 -1 -2 1 2 102 -1 67 -106 18

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 130 112 136 262 209 153 136 103 137 170 158 171
Inventory Days 120 85 90 95 91 109 111 101 100 121 145 117
Days Payable 87 75 64 67 73 58 84 69 72 103 122 116
Cash Conversion Cycle 163 123 161 290 228 204 163 135 165 188 182 172
Working Capital Days 14 29 91 177 149 127 144 90 110 143 144 145
ROCE % 35% 33% 22% 3% 5% 12% 11% 23% 20% 14% 15% 19%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
49.00% 43.85% 43.85% 43.85% 43.85% 43.85% 43.87% 43.87% 43.87% 43.87% 43.87% 43.87%
4.23% 15.11% 14.90% 15.07% 15.55% 15.57% 18.59% 21.31% 21.95% 22.19% 19.89% 16.92%
0.96% 1.46% 3.65% 4.02% 4.76% 5.17% 3.75% 4.10% 4.30% 4.55% 5.50% 5.28%
45.79% 39.57% 37.60% 37.06% 35.81% 35.40% 33.77% 30.70% 29.88% 29.37% 30.74% 33.93%
No. of Shareholders 2,13,1231,98,3821,88,4472,07,9372,37,3772,54,6992,35,5002,48,8452,59,8132,57,2732,56,2212,65,788

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls